ifosfamide has been researched along with Hematologic Diseases in 45 studies
Hematologic Diseases: Disorders of the blood and blood forming tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Based on the promising results of a Phase I study with a combination of gemcitabine and DTIC performed in advanced soft tissue sarcoma (ASTS) patients, and due to the limited efficacy of second or third line therapies in those patients, we designed a Phase II study to determine the activity of this new regimen." | 9.12 | Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas. ( Buesa, JM; Del Muro, JG; Escudero, P; Esteban, E; Fra, J; Gión, M; Goitia, A; López-Pousa, A; Losa, R; Maurel, J; Nadal, R; Sierra, M; Uña, E, 2007) |
| "The aim of this phase II study was to evaluate the efficacy and toxicity of two regimens of ifosfamide in metastatic soft tissue sarcoma patients given as first- and second-line chemotherapy." | 9.10 | Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. ( Dombernowsky, P; Hermans, C; Judson, I; Krzemieniecki, K; Mouridsen, HT; Nielsen, OS; Spooner, D; Svancarova, L; Van Glabbeke, M; van Oosterom, AT; Verweij, J, 2002) |
| "The efficacy and feasibility of a novel sequential schedule of high-dose ifosfamide (HD-IFO) and full-dose epirubicin (EPI) with granulocyte colony-stimulating factor (G-CSF) was evaluated in adult patients with soft tissue sarcomas (STS)." | 9.09 | A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule. ( Cognetti, F; Gamucci, T; Nardi, M; Serrone, L; Zeuli, M, 2001) |
| "A Phase II study of VP-16 (etoposide), ifosfamide/mesna, and cisplatin (VIP) in advanced and recurrent carcinoma of the cervix was initiated March 1989." | 7.68 | Etoposide (VP-16), ifosfamide/mesna, and cisplatin chemotherapy for advanced and recurrent carcinoma of the cervix. ( Kredentser, DC, 1991) |
| "To evaluate safety and pharmacokinetics and to establish the maximum tolerated dose of glufosfamide when administered in combination with gemcitabine in advanced solid tumors." | 6.73 | A Phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma. ( Chiorean, EG; Colowick, AB; Dragovich, T; Hamm, J; Jung, DT; Kroll, S; Langmuir, VK; Loehrer, PJ; Tidmarsh, GF, 2008) |
| " In the present analysis, we retrospectively investigated the feasibility and effectiveness of bevacizumab combined with ICE in patients with glioblastoma at second relapse during ICE treatment." | 5.39 | Retrospective analysis of bevacizumab in combination with ifosfamide, carboplatin, and etoposide in patients with second recurrence of glioblastoma. ( Arakawa, Y; Fujimoto, K; Kikuchi, T; Kunieda, T; Miyamoto, S; Mizowaki, T; Murata, D; Takagi, Y; Takahashi, JC, 2013) |
| "Based on the promising results of a Phase I study with a combination of gemcitabine and DTIC performed in advanced soft tissue sarcoma (ASTS) patients, and due to the limited efficacy of second or third line therapies in those patients, we designed a Phase II study to determine the activity of this new regimen." | 5.12 | Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas. ( Buesa, JM; Del Muro, JG; Escudero, P; Esteban, E; Fra, J; Gión, M; Goitia, A; López-Pousa, A; Losa, R; Maurel, J; Nadal, R; Sierra, M; Uña, E, 2007) |
| "The aim of this phase II study was to evaluate the efficacy and toxicity of two regimens of ifosfamide in metastatic soft tissue sarcoma patients given as first- and second-line chemotherapy." | 5.10 | Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. ( Dombernowsky, P; Hermans, C; Judson, I; Krzemieniecki, K; Mouridsen, HT; Nielsen, OS; Spooner, D; Svancarova, L; Van Glabbeke, M; van Oosterom, AT; Verweij, J, 2002) |
| "The efficacy and feasibility of a novel sequential schedule of high-dose ifosfamide (HD-IFO) and full-dose epirubicin (EPI) with granulocyte colony-stimulating factor (G-CSF) was evaluated in adult patients with soft tissue sarcomas (STS)." | 5.09 | A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule. ( Cognetti, F; Gamucci, T; Nardi, M; Serrone, L; Zeuli, M, 2001) |
| "We have reported the results of a previous Phase II trial of two courses of neoadjuvant mitomycin (6 mg/m2), ifosfamide (3 g/m2) and cisplatin (50 mg/m2) (MIC) in squamous or anaplastic carcinoma of the oesophagus." | 5.08 | A phase II trial of four courses of preoperative chemotherapy in squamous or anaplastic carcinoma of the oesophagus. ( Cullen, MH; Darnton, SJ; Matthews, HR; McAleer, JA; McManus, KG; Steyn, RS, 1998) |
| "A Phase II study of VP-16 (etoposide), ifosfamide/mesna, and cisplatin (VIP) in advanced and recurrent carcinoma of the cervix was initiated March 1989." | 3.68 | Etoposide (VP-16), ifosfamide/mesna, and cisplatin chemotherapy for advanced and recurrent carcinoma of the cervix. ( Kredentser, DC, 1991) |
| "The European Intergroup Cooperative Ewing's Sarcoma Study investigated whether cyclophosphamide has a similar efficacy as ifosfamide in standard-risk (SR) patients and whether the addition of etoposide improves survival in high-risk (HR) patients." | 2.73 | Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. ( Cassoni, A; Craft, AW; Douglas, C; Dunst, J; Grimer, R; Hackshaw, A; Hunold, A; Jürgens, H; Köhler, G; Ladenstein, R; Lewis, I; McTiernan, A; Paulussen, M; Poremba, C; Schuck, A; Spooner, D; van den Berg, H; Whelan, J; Winkelmann, W; Zoubek, A, 2008) |
| "To evaluate safety and pharmacokinetics and to establish the maximum tolerated dose of glufosfamide when administered in combination with gemcitabine in advanced solid tumors." | 2.73 | A Phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma. ( Chiorean, EG; Colowick, AB; Dragovich, T; Hamm, J; Jung, DT; Kroll, S; Langmuir, VK; Loehrer, PJ; Tidmarsh, GF, 2008) |
| "The prognosis of advanced ovarian cancer is very poor, with about 15% of patients surviving at five years." | 2.68 | Ifosfamide seven-day infusion for recurrent and cisplatin refractory ovarian cancer. ( Beuzeboc, P; Dorval, T; Garcia-Giralt, E; Jouve, M; Livartowski, A; Mosseri, V; Palangié, T; Pouillart, P; Sastre, X; Scholl, S; Soussain, C, 1996) |
| "Etoposide has reported synergism with these alkylators and produces mucositis as its dose-limiting toxicity." | 2.67 | High-dose ifosfamide/carboplatin/etoposide with autologous hematopoietic stem cell support: safety and future directions. ( Antman, KH; Ayash, LJ; Elias, AD; Frei, E; Mazanet, R; McCauley, M; Schnipper, L; Schwartz, G; Tepler, I; Wheeler, C, 1994) |
| "Ifosfamide/mesna has activity in a wide range of gynecologic malignancies." | 2.67 | Gynecologic Oncology Group experience with ifosfamide. ( Berman, ML; Blessing, JA; Homesley, HD; Photopulos, G; Sutton, GP, 1990) |
| " The aim of this study was to assess the efficacy and safety of ifosfamide in combination with carboplatin and etoposide (ICE) in previously untreated patients with SCLC." | 1.42 | Efficacy and safety of ifosfamide in combination with carboplatin and etoposide in small cell lung cancer. ( Koo, DH; Lee, HS; Lee, SS; Lee, YG; Lim, SY; Nam, H; Oh, S; Song, JU, 2015) |
| " In the present analysis, we retrospectively investigated the feasibility and effectiveness of bevacizumab combined with ICE in patients with glioblastoma at second relapse during ICE treatment." | 1.39 | Retrospective analysis of bevacizumab in combination with ifosfamide, carboplatin, and etoposide in patients with second recurrence of glioblastoma. ( Arakawa, Y; Fujimoto, K; Kikuchi, T; Kunieda, T; Miyamoto, S; Mizowaki, T; Murata, D; Takagi, Y; Takahashi, JC, 2013) |
| "The adverse effects of combination chemotherapy of ifosfamide, cisplatin, and etoposide (ICE) were evaluated in the treatment of various intracranial brain tumors." | 1.36 | [The safety of combination chemotherapy with ifosfamide, cisplatin, and etoposide (ICE): single-institution retrospective review of 108 cases]. ( Kanamori, M; Kumabe, T; Saito, R; Sonoda, Y; Tominaga, T; Yamashita, Y, 2010) |
| " This observation suggests a strategy of individualized dosing adapted to hematotoxicity." | 1.32 | Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease. ( Brosteanu, O; Diehl, V; Hasenclever, D; Loeffler, M, 2004) |
| "Ifosfamide was given to 61 patients with malignant solid tumors diagnosed before the age of 21 years." | 1.27 | Phase II trial of ifosfamide in children with malignant solid tumors. ( Douglass, EC; Etcubanas, E; Green, AA; Hayes, FA; Horowitz, ME; Meyer, WH; Pratt, CB; Thompson, EI; Wilimas, JA, 1987) |
| "Forty-seven patients with Hodgkin's disease in relapse were treated with MIME combination chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide)." | 1.27 | MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease. ( Cabanillas, F; Hagemeister, FB; McLaughlin, P; Riggs, S; Salvador, P; Tannir, N; Velasquez, WS, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (11.11) | 18.7374 |
| 1990's | 19 (42.22) | 18.2507 |
| 2000's | 15 (33.33) | 29.6817 |
| 2010's | 6 (13.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mikesch, JH | 1 |
| Kuhlmann, M | 1 |
| Demant, A | 1 |
| Krug, U | 1 |
| Thoennissen, GB | 1 |
| Schmidt, E | 1 |
| Kessler, T | 1 |
| Schliemann, C | 1 |
| Pohlen, M | 1 |
| Mohr, M | 2 |
| Evers, G | 1 |
| Köhler, G | 2 |
| Wessling, J | 1 |
| Mesters, R | 1 |
| Müller-Tidow, C | 1 |
| Berdel, WE | 2 |
| Thoennissen, NH | 1 |
| Paioli, A | 1 |
| Luksch, R | 1 |
| Fagioli, F | 1 |
| Tamburini, A | 1 |
| Cesari, M | 1 |
| Palmerini, E | 1 |
| Abate, ME | 1 |
| Marchesi, E | 1 |
| Balladelli, A | 1 |
| Pratelli, L | 1 |
| Ferrari, S | 1 |
| Arakawa, Y | 1 |
| Mizowaki, T | 1 |
| Murata, D | 1 |
| Fujimoto, K | 1 |
| Kikuchi, T | 1 |
| Kunieda, T | 1 |
| Takahashi, JC | 1 |
| Takagi, Y | 1 |
| Miyamoto, S | 1 |
| Tanaka, H | 1 |
| Yuasa, T | 1 |
| Fujii, Y | 1 |
| Sakura, M | 1 |
| Urakami, S | 1 |
| Yamamoto, S | 1 |
| Masuda, H | 1 |
| Fukui, I | 1 |
| Yonese, J | 1 |
| Lee, HS | 1 |
| Lee, YG | 1 |
| Koo, DH | 1 |
| Oh, S | 1 |
| Nam, H | 1 |
| Song, JU | 1 |
| Lim, SY | 2 |
| Lee, SS | 1 |
| Paulussen, M | 1 |
| Craft, AW | 1 |
| Lewis, I | 1 |
| Hackshaw, A | 1 |
| Douglas, C | 1 |
| Dunst, J | 1 |
| Schuck, A | 1 |
| Winkelmann, W | 1 |
| Poremba, C | 1 |
| Zoubek, A | 1 |
| Ladenstein, R | 1 |
| van den Berg, H | 1 |
| Hunold, A | 1 |
| Cassoni, A | 1 |
| Spooner, D | 3 |
| Grimer, R | 1 |
| Whelan, J | 1 |
| McTiernan, A | 1 |
| Jürgens, H | 1 |
| Kanamori, M | 1 |
| Kumabe, T | 1 |
| Saito, R | 1 |
| Yamashita, Y | 1 |
| Sonoda, Y | 1 |
| Tominaga, T | 1 |
| Marx, G | 1 |
| Lewis, C | 1 |
| Hall, K | 1 |
| Levi, J | 1 |
| Ackland, S | 1 |
| Oelmann, E | 1 |
| Thomas, M | 1 |
| Serve, H | 1 |
| Kienast, J | 1 |
| Zühlsdorf, M | 1 |
| Klinke, F | 1 |
| Dölken, G | 1 |
| Macha, H | 1 |
| Schmidt, EW | 1 |
| van Oosterom, AT | 1 |
| Mouridsen, HT | 1 |
| Nielsen, OS | 1 |
| Dombernowsky, P | 1 |
| Krzemieniecki, K | 1 |
| Judson, I | 1 |
| Svancarova, L | 1 |
| Hermans, C | 1 |
| Van Glabbeke, M | 1 |
| Verweij, J | 1 |
| Kremens, B | 1 |
| Gruhn, B | 1 |
| Klingebiel, T | 1 |
| Hasan, C | 1 |
| Laws, HJ | 1 |
| Koscielniak, E | 1 |
| Hero, B | 1 |
| Selle, B | 1 |
| Niemeyer, C | 1 |
| Finckenstein, FG | 1 |
| Schulz, A | 1 |
| Wawer, A | 1 |
| Zintl, F | 1 |
| Graf, N | 1 |
| van Rijswijk, RE | 1 |
| Vermorken, JB | 1 |
| Reed, N | 1 |
| Favalli, G | 1 |
| Mendiola, C | 1 |
| Zanaboni, F | 1 |
| Mangili, G | 1 |
| Vergote, I | 1 |
| Guastalla, JP | 1 |
| ten Bokkel Huinink, WW | 1 |
| Lacave, AJ | 1 |
| Bonnefoi, H | 1 |
| Tumulo, S | 1 |
| Rietbroek, R | 1 |
| Teodorovic, I | 1 |
| Coens, C | 1 |
| Pecorelli, S | 1 |
| Brosteanu, O | 1 |
| Hasenclever, D | 1 |
| Loeffler, M | 1 |
| Diehl, V | 1 |
| Boutemy, M | 1 |
| Mispelaere, D | 1 |
| Krzisch, C | 1 |
| Jounieaux, V | 1 |
| Losa, R | 1 |
| Fra, J | 1 |
| López-Pousa, A | 1 |
| Sierra, M | 1 |
| Goitia, A | 1 |
| Uña, E | 1 |
| Nadal, R | 1 |
| Del Muro, JG | 1 |
| Gión, M | 1 |
| Maurel, J | 1 |
| Escudero, P | 1 |
| Esteban, E | 1 |
| Buesa, JM | 1 |
| Lin, CC | 1 |
| Hsu, CH | 1 |
| Huang, CY | 1 |
| Keng, HY | 1 |
| Tsai, YC | 1 |
| Huang, KH | 1 |
| Cheng, AL | 1 |
| Pu, YS | 1 |
| Chiorean, EG | 1 |
| Dragovich, T | 1 |
| Hamm, J | 1 |
| Langmuir, VK | 1 |
| Kroll, S | 1 |
| Jung, DT | 1 |
| Colowick, AB | 1 |
| Tidmarsh, GF | 1 |
| Loehrer, PJ | 3 |
| Leyvraz, S | 1 |
| Pampallona, S | 1 |
| Martinelli, G | 1 |
| Ploner, F | 1 |
| Perey, L | 1 |
| Aversa, S | 1 |
| Peters, S | 1 |
| Brunsvig, P | 1 |
| Montes, A | 1 |
| Lange, A | 1 |
| Yilmaz, U | 1 |
| Rosti, G | 3 |
| Williams, SD | 1 |
| Einhorn, LH | 2 |
| Fields, KK | 1 |
| Elfenbein, GJ | 1 |
| Perkins, JB | 1 |
| Janssen, WE | 1 |
| Ballester, OF | 1 |
| Hiemenz, JW | 1 |
| Zorsky, PE | 1 |
| Kronish, LE | 1 |
| Foody, MC | 1 |
| Faylona, EA | 1 |
| Ansari, R | 1 |
| Sandler, AB | 1 |
| Gonin, R | 1 |
| Elias, AD | 2 |
| Ayash, LJ | 2 |
| Wheeler, C | 2 |
| Schwartz, G | 1 |
| Tepler, I | 1 |
| McCauley, M | 1 |
| Mazanet, R | 1 |
| Schnipper, L | 2 |
| Frei, E | 1 |
| Antman, KH | 2 |
| Fridrik, MA | 1 |
| Hausmaninger, H | 1 |
| Linkesch, W | 1 |
| Stöger, M | 1 |
| Sill, H | 1 |
| Neubauer, M | 1 |
| Seewann, HL | 1 |
| Klocker, J | 1 |
| Haidinger, R | 1 |
| Schiller, L | 1 |
| Pont, J | 1 |
| Raudaschl, G | 1 |
| Falk, M | 1 |
| Radaszkiewicz, T | 1 |
| Welte, K | 1 |
| Reiter, A | 1 |
| Mempel, K | 1 |
| Pfetsch, M | 1 |
| Schwab, G | 1 |
| Schrappe, M | 1 |
| Riehm, H | 1 |
| Shepherd, FA | 1 |
| Latreille, J | 1 |
| Crump, M | 1 |
| Stewart, D | 1 |
| Tomiak, E | 1 |
| Eisenhauer, E | 1 |
| Fisher, B | 1 |
| Dorval, T | 1 |
| Soussain, C | 1 |
| Beuzeboc, P | 1 |
| Garcia-Giralt, E | 1 |
| Jouve, M | 1 |
| Livartowski, A | 1 |
| Mosseri, V | 1 |
| Palangié, T | 1 |
| Scholl, S | 1 |
| Sastre, X | 1 |
| Pouillart, P | 1 |
| Scagliotti, GV | 1 |
| Ricardi, U | 1 |
| Crinó, L | 1 |
| Maranzano, E | 1 |
| De Marinis, F | 1 |
| Morandi, MG | 1 |
| Meacci, L | 1 |
| Marangolo, M | 2 |
| Emiliani, E | 1 |
| Figoli, F | 1 |
| Bolzicco, G | 1 |
| Masiero, P | 1 |
| Gentile, A | 1 |
| Tonato, M | 1 |
| Steyn, RS | 1 |
| Darnton, SJ | 1 |
| McManus, KG | 1 |
| McAleer, JA | 1 |
| Cullen, MH | 1 |
| Matthews, HR | 1 |
| Urban, C | 1 |
| Benesch, M | 1 |
| Pakisch, B | 1 |
| Lackner, H | 1 |
| Kerbl, R | 1 |
| Schwinger, W | 1 |
| Oberbauer, R | 1 |
| Fujita, A | 1 |
| Takabatake, H | 1 |
| Tagaki, S | 1 |
| Sekine, K | 1 |
| Serrone, L | 1 |
| Zeuli, M | 1 |
| Gamucci, T | 1 |
| Nardi, M | 1 |
| Cognetti, F | 1 |
| De Giorgi, U | 1 |
| Papiani, G | 1 |
| Abu-Ghosh, AM | 1 |
| Krailo, MD | 1 |
| Goldman, SC | 1 |
| Slack, RS | 1 |
| Davenport, V | 1 |
| Morris, E | 1 |
| Laver, JH | 1 |
| Reaman, GH | 1 |
| Cairo, MS | 1 |
| von Rohr, A | 1 |
| Anderson, H | 1 |
| McIntosh, R | 1 |
| Thatcher, N | 1 |
| Hannigan, EV | 1 |
| Dinh, TV | 1 |
| Doherty, MG | 1 |
| Kredentser, DC | 1 |
| Eder, JP | 1 |
| Deary, J | 1 |
| Weissman, L | 1 |
| Schryber, S | 1 |
| Hunt, M | 1 |
| Critchlow, J | 1 |
| Araujo, CE | 1 |
| Cervellino, JC | 1 |
| Pirisi, C | 1 |
| Pannunzio, O | 1 |
| Callegari, J | 1 |
| Lotz, JP | 1 |
| Machover, D | 1 |
| Malassagne, B | 1 |
| Hingh, B | 1 |
| Donsimoni, R | 1 |
| Gumus, Y | 1 |
| Gerota, J | 1 |
| Lam, Y | 1 |
| Tulliez, M | 1 |
| Marsiglia, H | 1 |
| Elias, A | 1 |
| Ryan, L | 1 |
| Sutton, GP | 1 |
| Blessing, JA | 1 |
| Photopulos, G | 1 |
| Berman, ML | 1 |
| Homesley, HD | 1 |
| Meanwell, CA | 1 |
| Mould, JJ | 1 |
| Blackledge, G | 1 |
| Lawton, FG | 1 |
| Stuart, NS | 1 |
| Kavanagh, J | 1 |
| Latief, TN | 1 |
| Chetiyawardana, AD | 1 |
| Pratt, CB | 1 |
| Horowitz, ME | 1 |
| Meyer, WH | 1 |
| Etcubanas, E | 1 |
| Thompson, EI | 1 |
| Douglass, EC | 1 |
| Wilimas, JA | 1 |
| Hayes, FA | 1 |
| Green, AA | 1 |
| Case, DC | 1 |
| Anderson, J | 1 |
| Ervin, TJ | 1 |
| Gottlieb, A | 1 |
| Hagemeister, FB | 1 |
| Tannir, N | 1 |
| McLaughlin, P | 1 |
| Salvador, P | 1 |
| Riggs, S | 1 |
| Velasquez, WS | 1 |
| Cabanillas, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Functional and Clinical Long-Term Outcome of Ewing Sarcoma Treatment[NCT00824083] | 950 participants (Actual) | Observational | 2009-07-31 | Completed | |||
| Chemotherapy-induced Necrosis in Ewing Sarcoma: Which is the Best Scoring Tool[NCT03968471] | 474 participants (Actual) | Observational | 2019-05-13 | Completed | |||
| EUROPEAN INTERGROUP COOPERATIVE EWING'S SARCOMA STUDY [EICESS 92][NCT00002516] | Phase 3 | 0 participants | Interventional | 1992-07-31 | Active, not recruiting | ||
| A Phase II Multicenter Trial of RAD001 in Patients With Metastatic or Recurrent Sarcomas[NCT01830153] | Phase 2 | 41 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for ifosfamide and Hematologic Diseases
| Article | Year |
|---|---|
The status of high-dose chemotherapy with hematopoietic stem cell transplantation in germ cell tumor patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Cisplatin; Clinical T | 2002 |
27 trials available for ifosfamide and Hematologic Diseases
| Article | Year |
|---|---|
Chemotherapy-related toxicity in patients with non-metastatic Ewing sarcoma: influence of sex and age.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chil | 2014 |
Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2008 |
Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2008 |
Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2008 |
Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2008 |
Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2008 |
Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2008 |
Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2008 |
Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2008 |
Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2008 |
Phase I study of docetaxel plus ifosfamide in patients with advanced cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Respons | 2002 |
Early tandem high-dose ifosfamide, carboplatin, etoposide therapy with stem cell rescue for small-cell lung cancer: brief report on the results of a phase-I/II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carboplatin; Carcinom | 2002 |
Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Disease Progression; Dose-Response Relationship, Dru | 2002 |
Cisplatin, doxorubicin and ifosfamide in carcinosarcoma of the female genital tract. A phase II study of the European Organization for Research and Treatment of Cancer Gynaecological Cancer Group (EORTC 55923).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Cisplatin; Doxorubicin; | 2003 |
Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas.
Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; | 2007 |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: a phase II study.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; An | 2007 |
A Phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2008 |
A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Co | 2008 |
High-dose ifosfamide/carboplatin/etoposide: maximum tolerable doses, toxicities, and hematopoietic recovery after autologous stem cell reinfusion.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relati | 1994 |
Phase II study of daily oral etoposide plus ifosfamide plus cisplatin for previously treated recurrent small-cell lung cancer: a Hoosier Oncology Group Trial.
Topics: Administration, Oral; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Carcino | 1995 |
High-dose ifosfamide/carboplatin/etoposide with autologous hematopoietic stem cell support: safety and future directions.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Forecasting; Hematolo | 1994 |
CEOP-IMVP-Dexa in the treatment of aggressive lymphomas: an Austrian multicenter trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexametha | 1996 |
A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Münster Study Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 1996 |
Phase I study of paclitaxel (Taxol) and ifosfamide in previously untreated patients with advanced non-small-cell lung cancer. A study of the National Cancer Institute of Canada Clinical Trials Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Canada; Carcinoma, Non-Small-Cell Lung; | 1996 |
Ifosfamide seven-day infusion for recurrent and cisplatin refractory ovarian cancer.
Topics: Adult; Aged; Alopecia; Ambulatory Care; Antineoplastic Agents, Alkylating; Female; Hematologic Disea | 1996 |
Phase II study of intensive chemotherapy with carboplatin, ifosfamide and etoposide plus recombinant human granulocyte colony-stimulating factor and sequential radiotherapy in locally advanced, unresectable non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, | 1996 |
A phase II trial of four courses of preoperative chemotherapy in squamous or anaplastic carcinoma of the oesophagus.
Topics: Adult; Aged; Alopecia; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Al | 1998 |
Synchronous radiochemotherapy in unfavorable brain tumors of children and young adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Che | 1998 |
Phase I study of cisplatin, ifosfamide and irinotecan with rhG-CSF support in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Co | 1999 |
A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule.
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemot | 2001 |
Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms' tumor: a Children's Cancer Group report.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child, Preschool; Etoposide | 2002 |
A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Com | 1991 |
Phase I-II study of two consecutive courses of high-dose epipodophyllotoxin, ifosfamide, and carboplatin with autologous bone marrow transplantation for treatment of adult patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplati | 1991 |
Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Child; Chil | 1990 |
Gynecologic Oncology Group experience with ifosfamide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; | 1990 |
17 other studies available for ifosfamide and Hematologic Diseases
| Article | Year |
|---|---|
DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Co | 2013 |
Retrospective analysis of bevacizumab in combination with ifosfamide, carboplatin, and etoposide in patients with second recurrence of glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2013 |
First-line combination chemotherapy with cisplatin, etoposide and ifosfamide for the treatment of disseminated germ cell cancer: re-evaluation in the granulocyte colony-stimulating factor era.
Topics: Adult; Antineoplastic Agents; Cisplatin; Disease-Free Survival; Drug Therapy, Combination; Etoposide | 2013 |
Efficacy and safety of ifosfamide in combination with carboplatin and etoposide in small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Sma | 2015 |
[The safety of combination chemotherapy with ifosfamide, cisplatin, and etoposide (ICE): single-institution retrospective review of 108 cases].
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, | 2010 |
High-dose chemotherapy with autologous stem cell rescue in children with nephroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Combined Modal | 2002 |
Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; Cohort Studies; Cyclophospha | 2004 |
[Evaluation of combined chemotherapy with vinorelbine, ifosfamide and cisplatin in the treatment of metastatic non-small cell bronchial carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcin | 2005 |
N-acetylcysteine and ifosfamide in the treatment of unresectable pancreatic adenocarcinoma and refractory testicular cancer.
Topics: Acetylcysteine; Adenocarcinoma; Adult; Aged; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combin | 1983 |
Phase II study with mitomycin, ifosfamide and carboplatin in inoperable non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; D | 1991 |
Ifosfamide with mesna in squamous carcinoma of the cervix: phase II results in patients with advanced or recurrent disease.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Drug Evaluation; Drug Therapy, Combination; Female; Hematolog | 1991 |
Etoposide (VP-16), ifosfamide/mesna, and cisplatin chemotherapy for advanced and recurrent carcinoma of the cervix.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Etoposide; Female | 1991 |
Chemotherapy with high dose ifosfamide/mesna plus cisplatin for the treatment of ovarian cancer: a study of the Grupo de Estudio y Tratamiento Latino-Americano del Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Femal | 1991 |
Phase II study of ifosfamide in cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Central Nervo | 1986 |
Phase II trial of ifosfamide in children with malignant solid tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Drug Eva | 1987 |
Phase II trial of ifosfamide and mesna in previously treated patients with non-Hodgkin's lymphoma: Cancer and Leukemia Group B Study 8552.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Drug Evaluation; Hematologic Diseases; Hematuria; Humans | 1988 |
MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Hematologic Di | 1987 |